Cite
Real-world adherence and treatment discontinuation with trifluridine/tipiracil (FTD-TPI) compared with regorafenib (REG) for the treatment of metastatic colorectal cancer (mCRC)
MLA
Yongling Xiao, et al. “Real-World Adherence and Treatment Discontinuation with Trifluridine/Tipiracil (FTD-TPI) Compared with Regorafenib (REG) for the Treatment of Metastatic Colorectal Cancer (MCRC).” Journal of Clinical Oncology, vol. 35, May 2017, p. e15000. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........7748816218501689375ee9b2056082cc&authtype=sso&custid=ns315887.
APA
Yongling Xiao, Mihran Ara Yenikomshian, Mei Sheng Duh, Anuj K. Patel, Majid Tabesh, Willy Wynant, Victoria Barghout, & Charles S. Fuchs. (2017). Real-world adherence and treatment discontinuation with trifluridine/tipiracil (FTD-TPI) compared with regorafenib (REG) for the treatment of metastatic colorectal cancer (mCRC). Journal of Clinical Oncology, 35, e15000.
Chicago
Yongling Xiao, Mihran Ara Yenikomshian, Mei Sheng Duh, Anuj K. Patel, Majid Tabesh, Willy Wynant, Victoria Barghout, and Charles S. Fuchs. 2017. “Real-World Adherence and Treatment Discontinuation with Trifluridine/Tipiracil (FTD-TPI) Compared with Regorafenib (REG) for the Treatment of Metastatic Colorectal Cancer (MCRC).” Journal of Clinical Oncology 35 (May): e15000. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........7748816218501689375ee9b2056082cc&authtype=sso&custid=ns315887.